Investor Briefing – TheraPharm GmbH Acquisition
Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH…
Read moreNews & Views
Investor Conference Call: Telix’s acquisition of TheraPharm GmbH
Telix advises it will hold an investor conference call to provide further detail in relation to Telix’s acquisition of TheraPharm…
Read more
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH
Telix announces it has entered into an agreement with Scintec Diagnostics GmbH to acquire TheraPharm GmbH, a Swiss-German biotechnology company developing innovative diagnostic and therapeutic solutions in the field of…
Read more
Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation…
Read more
Telix Presentation at the European Multidisciplinary Congress on Urological Cancers
Telix recently presented at the 12th European Multidisciplinary Congress on Urological Cancers entitled: “New Perspectives in Prostate and Kidney…
Read more
Telix Receives €545,000 Belgian Research Grant for Prostate Cancer Imaging Agent in Europe
Advanced Nuclear Medicine Ingredients S.A. (ANMI) announces a €545,000 payment from the Walloon regional government in…
Read more
Telix presentations at European Association of Nuclear Medicine 2020 Satellite Symposium
Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of…
Read more
Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership
Telix Pharmaceuticals Provides Investor Briefing: Our Asian…
Read more
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China…
Read more
Activity Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging…
Read more